Literature DB >> 20447550

ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature.

Matthias Eder1, Arcadius V Krivoshein, Marina Backer, Joseph M Backer, Uwe Haberkorn, Michael Eisenhut.   

Abstract

INTRODUCTION: VEGF receptors play a key role in angiogenesis and are important targets for several approved and many experimental drugs. Imaging of VEGF receptor expression in malignant tumors would provide important information, which can influence patient management. The aim of this study was the development of an easy-to-label positron-emitting tracer for imaging VEGF receptors. The tracer is based on engineered single-chain VEGF (scVEGF), expressed with cysteine-containing fusion tag (Cys-tag) for site-specific conjugation of PEGylated bifunctional chelating agents, HBED-CC or NOTA, suitable for labeling with (68)Ga at ambient temperature.
METHODS: scVEGF-PEG-HBED-CC was synthesized by activating a single carboxyl group of the [Fe(HBED-CC)](-) complex with N-hydroxysuccinimide. Reaction of the activated complex with NH(2)-PEG-maleimide was followed by site-specific conjugation of PEGylated chelator to a thiol group in Cys-tag of scVEGF. The scVEGF-PEG-NOTA conjugate was synthesized using NHS-PEG-maleimide and p-NH(2)-Bn-NOTA. (68)Ga complexation was performed in HEPES buffer (pH 4.2) at room temperature. The functional activity after labeling was tested by radioligand cell binding assays. Biodistribution and PET studies in tumor-bearing mice were performed after 1, 2, 3 and 4 h postinjection.
RESULTS: The radiolabeling of scVEGF-PEG-HBED-CC proved more efficient than scVEGF-PEG-NOTA allowing to stop the reaction after 4 min (>97% radiochemical yield). Radioligand cell binding assays performed on HEK-293 cells overexpressing VEGFR-2 revealed no change in the binding properties of (68)Ga-radiolabeled scVEGF relative to other scVEGF-based tracers. Both tracers showed comparable results in biodistribution, such as tumor accumulation and low liver uptake. The tracers were stable in 50% human serum for at least 72 h.
CONCLUSIONS: The conjugates scVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA revealed comparable in vivo characteristics and allowed easy-to-perform labeling with high stability for fast [(68)Ga]PET imaging of VEGF receptors in angiogenic vasculature. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447550     DOI: 10.1016/j.nucmedbio.2010.02.001

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  22 in total

1.  Targeting therapy of choroidal neovascularization by use of polypeptide- and PEDF-loaded immunoliposomes under ultrasound exposure.

Authors:  Tao Li; Ming Zhang; Yong Han; Hong Zhang; Lingjuan Xu; Yan Xiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

Review 2.  68Ga-DOTA and analogs: Current status and future perspectives.

Authors:  Krzysztof Kilian
Journal:  Rep Pract Oncol Radiother       Date:  2014-05-19

3.  Synthesis and assessment of ZD2-(68Ga-NOTA) specific to extradomain B fibronectin in tumor microenvironment for PET imaging of pancreatic cancer.

Authors:  Songqi Gao; Jingcan Qin; Olga Sergeeva; Maxim Sergeev; Peter Qiao; Sarah Roelle; Norbert Avril; Zhenghong Lee; Yajuan Li; Zhengrong Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

4.  Alternative Non-Antibody Protein Scaffolds for Molecular Imaging of Cancer.

Authors:  Lawrence A Stern; Brett A Case; Benjamin J Hackel
Journal:  Curr Opin Chem Eng       Date:  2013-11       Impact factor: 5.163

5.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

6.  In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models.

Authors:  Choong Mo Kang; Sung-Min Kim; Hyun-Jung Koo; Min Su Yim; Kyung-Han Lee; Eun Kyoung Ryu; Yearn Seong Choe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-25       Impact factor: 9.236

7.  In vivo evaluation of medical device-associated inflammation using a macrophage-specific positron emission tomography (PET) imaging probe.

Authors:  Jun Zhou; Guiyang Hao; Hong Weng; Yi-Ting Tsai; David W Baker; Xiankai Sun; Liping Tang
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

Review 8.  New radiotracers for imaging of vascular targets in angiogenesis-related diseases.

Authors:  Hao Hong; Feng Chen; Yin Zhang; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2014-07-30       Impact factor: 15.470

9.  Positron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF121.

Authors:  Yin Zhang; Hao Hong; Gang Niu; Hector F Valdovinos; Hakan Orbay; Tapas R Nayak; Xiaoyuan Chen; Todd E Barnhart; Weibo Cai
Journal:  Mol Pharm       Date:  2012-11-16       Impact factor: 4.939

10.  A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.

Authors:  Martin Schäfer; Ulrike Bauder-Wüst; Karin Leotta; Frederic Zoller; Walter Mier; Uwe Haberkorn; Michael Eisenhut; Matthias Eder
Journal:  EJNMMI Res       Date:  2012-06-06       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.